Researchers at Duke University Medical Center Target Stem Cells [Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial]
By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Stem Cell Research are discussed in a new report. According to news reporting from Durham, North Carolina, by NewsRx journalists, research stated, "Myeloablative chemoradiotherapy and immunomagnetically purged autologous bone marrow transplantation has been shown to improve outcome for patients with high-risk neuroblastoma. Currently, peripheral blood stem cells (PBSC) are infused after myeloablative therapy, but the effect of purging is unknown."
The news correspondents obtained a quote from the research from Duke University Medical Center, "We did a randomised study of tumour-selective PBSC purging in stem-cell transplantation for patients with high-risk neuroblastoma. Between March 16, 2001, and Feb 24, 2006, children and young adults (ClinicalTrials.gov, number NCT00004188. 495 patients were enrolled, of whom 486 were randomly assigned to treatment: 243 patients to receive non-purged PBSC and 243 to received purged PBSC. PBSC were collected from 229 patients from the purged group and 236 patients from the non-purged group, and 180 patients from the purged group and 192 from the non-purged group received transplant. 5-year event-free survival was 40% (95% CI 33-46) in the purged group versus 36% (30-42) in the non-purged group (p=0·77); 5-year overall survival was 50% (95% CI 43-56) in the purged group compared with 51% (44-57) in the non-purged group (p=0·81). Toxic deaths occurred in 15 patients during induction (eight in the purged group and seven in the non-purged group) and 12 during consolidation (eight in the purged group and four in the non-purged group). The most common adverse event reported was grade 3 or worse stomatitis during both induction (87 of 242 patients in the purged group and 93 of 243 patients in the non-purged group) and consolidation (131 of 177 in the purged group vs 145 of 191 in the non-purged group). Serious adverse events during induction were grade 3 or higher decreased cardiac function (four of 242 in the purged group and five of 243 in the non-purged group) and elevated creatinine (five of 242 in the purged group and six of 243 non-purged group) and during consolidation were sinusoidal obstructive syndrome (12 of 177 in the purged group and 17 of 191 in the non-purged group), acute vascular leak (11 of 177 in the purged group and nine of 191 in the non-purged group), and decreased cardiac function (one of 177 in the purged group and four of 191 in the non-purged group). Immunomagnetic purging of PBSC for autologous stem-cell transplantation did not improve outcome, perhaps because of incomplete purging or residual tumor in patients."
According to the news reporters, the research concluded: "Non-purged PBSC are acceptable for support of myeloablative therapy of high-risk neuroblastoma."
For more information on this research see: Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. The Lancet Oncology, 2013;14(10):999-1008 (see also Stem Cell Research).
Our news journalists report that additional information may be obtained by contacting S.G. Kreissman, Duke University Medical Center, Durham, NC, United States. Additional authors for this research include R.C. Seeger, K.K. Matthay, W.B. London, R. Sposto, S.A. Grupp, D.A. Haas-Kogan, M.P. Laquaglia, A.L. Yu, L. Diller, A. Buxton, J.R. Park, S.L. Cohn, J.M. Maris, C.P. Reynolds and J.G Villablanca.
Keywords for this news article include: Durham, Surgery, Therapy, Oncology, Cardiology, Hematology, United States, Neuroblastoma, North Carolina, Stem Cell Research, Cell Transplantation, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC